DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
<h4>Background</h4>Oestrogen receptor (ER) positive (luminal) tumours account for the largest proportion of females with breast cancer. Theirs is a heterogeneous disease presenting clinical challenges in managing their treatment. Three main biological luminal groups have been identified...
Guardado en:
Autores principales: | Desmond G Powe, Gopal Krishna R Dhondalay, Christophe Lemetre, Tony Allen, Hany O Habashy, Ian O Ellis, Robert Rees, Graham R Ball |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/65a8a8ef87a7433b922d346ad74caebd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer
por: Alba Orea-Soufi, et al.
Publicado: (2021) -
Communitybuilding über Discord – der DACH-Bibliothekswesen-Server
por: Victoria Geske, et al.
Publicado: (2021) -
DACH1 suppresses breast cancer as a negative regulator of CD44
por: Hanxiao Xu, et al.
Publicado: (2017) -
Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling.
por: Liang Wu, et al.
Publicado: (2014) -
A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma
por: Yang Peng, et al.
Publicado: (2021)